The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Activation of Nrf2/HO-1 Pathway by Nardochinoid C Inhibits Inflammation and Oxidative Stress in Lipopolysaccharide-Stimulated Macrophages
Open accessAbstract
The roots and rhizomes of Nardostachys chinensis have neuroprotection and cardiovascular protection effects. However, the specific mechanism of N. chinensis is not yet clear. Dinardokanshone C is a new compound with new backbone isolated from N. chinensis and this study for the first time explored the anti-inflammatory and anti-oxidant effect of dinardokanshone C. The results showed that dinardokanshone C significantly reduced the release of nitric oxide (NO) and prostaglandin E2 (PGE2) in lipopolysaccharide (LPS)-activated RAW264.7 cells. The expression of pro-inflammatory proteins including inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) were also obviously inhibited by dinardokanshone C. Besides, the production of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were also remarkably inhibited by dinardokanshone C. Furthermore, dinardokanshone C inhibited the macrophage M1 phenotype and the production of reactive oxygen species (ROS). Mechanism studies showed that dinardokanshone C mainly activated nuclear factor-E2-related factor 2 (Nrf2) signaling pathway, increased the level of anti-oxidant protein heme oxygenase-1(HO-1) and thus produced the anti-inflammatory and anti-oxidant effects, which were abolished by Nrf2 siRNA and HO-1 inhibitor. These findings suggested that dinardokanshone C could be a new Nrf2 activator for the treatment and prevention of diseases related to inflammation and oxidative stress. Keywords: Nardostachys chinensis; dinardokanshone C; Nrf2; HO-1; ROS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199
Xu, H., Barnes, G. T., Yang, Q., Tan, G., Yang, D., Chou, C. J., Sole, J., Nichols, A., Ross, J. S., Tartaglia, L. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319451 · Cited by 6,760
The Pathogenesis of Rheumatoid Arthritis
McInnes, I. B., & Schett, G. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1004965 · Cited by 5,514 · cited 3×
“Antioxidant protein HO-1 has anti-oxidative and antiinflammatory effects (Linton and Fazio, 2003; McInnes and Schett, 2011).”
BackgroundInflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Cancer chemoprevention with dietary phytochemicals
Surh, Y.-J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1189 · Cited by 2,955
Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription
Kobayashi, E. H., Suzuki, T., Funayama, R., Nagashima, T., Hayashi, M., Sekine, H., Tanaka, N., Moriguchi, T., Motohashi, H., Nakayama, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11624 · Cited by 1,878
Fujiwara, N., & Kobayashi, K. (2005) · Current Drug Target -Inflammation & Allergy · doi:10.2174/1568010054022024 · Cited by 1,420 · cited 1×
“, TNF-α and IL-6) to promote the development and progression of inflammation (Fujiwara and Kobayashi, 2005).”
BackgroundThe role of cyclooxygenases in inflammation, cancer, and development
Williams, C. S., Mann, M., & DuBois, R. N. (1999) · Oncogene · doi:10.1038/sj.onc.1203286 · Cited by 1,417
Macrophage-mediated inflammation in metabolic disease
Chawla, A., Nguyen, K. D., & Goh, Y. P. S. (2011) · Nature reviews. Immunology · doi:10.1038/nri3071 · Cited by 1,314
Kaminska, B. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.08.017 · Cited by 1,285
NRF2 and cancer: the good, the bad and the importance of context
Sporn, M. B., & Liby, K. T. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3278 · Cited by 1,067 · cited 1×
“, 2009), neurodegenerative diseases (Joshi and Johnson, 2012), cancer (Sporn and Liby, 2012), type 2 diabetes (Chartoumpekis and Kensler, 2013), chronic kidney disease (Ruiz et al.”
BackgroundActivation of Nrf2-antioxidant signaling attenuates NFκB-inflammatory response and elicits apoptosis
Li, W., Khor, T. O., Xu, C., Shen, G., Jeong, W.-S., Yu, S., & Kong, A.-N. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.07.017 · Cited by 738
Heme oxygenase–1, oxidation, inflammation, and atherosclerosis
Araujo, J. A., Zhang, M., & Yin, F. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00119 · Cited by 443
Cited by
An Overview of Nrf2 Signaling Pathway and Its Role in Inflammation
Saha, S., Buttari, B., Panieri, E., Profumo, E., & Saso, L. (2020) · Molecules · doi:10.3390/molecules25225474 · Cited by 1,388
Redox regulation of the immune response
Morris, G., Gevezova, M., Sarafian, V., & Maes, M. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-022-00902-0 · Cited by 575
Chen, Z., Zhong, H., Wei, J., Lin, S., Zong, Z., Gong, F., Huang, X., Sun, J., Li, P., Lin, H., et al. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-2085-6 · Cited by 275
Subedi, L., Lee, J., Yumnam, S., Ji, E., & Kim, S. (2019) · Cells · doi:10.3390/cells8020194 · Cited by 271
Li, W., Ali, T., He, K., Liu, Z., Shah, F. A., Ren, Q., Liu, Y., Jiang, A., & Li, S. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.11.008 · Cited by 263
Self-citation
Metadata
- Authors
- Luo, J.-F., Shen, X.-Y., Lio, C. K., Dai, Y., Cheng, C.-S., Liu, J.-X., Yao, Y.-D., Yu, Y., Xie, Y., Luo, P., Yao, X.-S., Liu, Z.-Q., & Zhou, H.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2018-09-04
- Volume
- 9
- Pages
- 911-911
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2889565370
- Cited by
- 180
- References
- 13
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.